Post-COVID-19 Cholangiopathy: A Novel Entity
- PMID: 33464757
- DOI: 10.14309/ajg.0000000000001154
Post-COVID-19 Cholangiopathy: A Novel Entity
Abstract
Introduction: Liver chemistry abnormalities are a frequent manifestation of coronavirus disease 2019 (COVID-19) but are usually transient and resolve with disease resolution.
Methods: We describe the clinical course and histologic features of 3 adults who developed prolonged and severe cholestasis during recovery from critical cardiopulmonary COVID-19.
Results: These patients had clinical and histologic features similar to secondary sclerosing cholangitis of the critically ill patient, but with unique histologic features including severe cholangiocyte injury and intrahepatic microangiopathy suggestive of direct hepatic injury from COVID-19.
Discussion: We believe that these cases constitute a novel severe post-COVID-19 cholangiopathy with potential for long-term hepatic morbidity.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
References
-
- Sharma A, Jaiswal P, Kerakhan Y, et al. Liver disease and outcomes among COVID-19 hospitalized patients – a systematic review and meta-analysis. Ann Hepatol 2021;21:100273.
-
- Hundt MA, Deng Y, Ciarleglio MM, et al. Abnormal liver tests in COVID-19: A retrospective observational cohort Study of 1827 patients in a major U.S. Hospital network. Hepatology 2020;72:1169–76.
-
- Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell 2020;11:771–5.
-
- Kirchner GI, Rümmele P. Update on sclerosing cholangitis in critically ill patients. Visc Med 2015;31:178–84.
-
- Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug‐induced liver injury: Systematic evaluation and clinical associations. Hepatology 2014;59:661–70.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
